<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[advisory committee and fda Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/advisory+committee+and+fda.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to advisory committee and fda]]></description>
	<s:counts start="0" returned="20" found="124" />
	<language>en-us</language>
	<item>
		<title><![CDATA[XenoPort, Inc. Q2 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-328784.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator  Operator instructions Your first question comes from the line of Eric Schmidt of Cowen and Company.  Eric Schmidt &#8211; Cowen and Company  Good afternoon. Thanks for taking my questions. Ron, has the FDA received the open-label expansion data for 512?  Ron Barrett ...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Wed, 05 Aug 2009 19:22:17 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/advisory+committee.html"><![CDATA[Advisory Committee]]></category>
		<category domain="http://resources.bnet.com/topic/eric+schmidt.html"><![CDATA[Eric Schmidt]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/xenoport+inc..html"><![CDATA[XenoPort Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">XNPT</category>
		<category domain="tickers">XNPT</category>
	</item>
	<item>
		<title><![CDATA[FDA Advisory Committee Votes in Favor of Approval of Fospropofol Disodium Injection for Sedation]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m4PRN/is_2008_May_7/ai_n25398472]]></link>
		<description><![CDATA[WOODCLIFF LAKE, N.J., May 7  /PRNewswire/ -- Eisai Corporation of North America and its U.S. subsidiary, MGI PHARMA, INC., today announced that the U.S. Food and Drug Administration FDA Advisory Committee on Anesthetic and Life Support Drugs ALSDAC has voted 6 to 3 in favor with one abstention of...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 07 May 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/advisory+committee.html"><![CDATA[advisory committee]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Lev Announces FDA Advisory Committee Unanimously Recommends Approval of Cinryze&#153; for Hereditary Angioedema]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_May_2/ai_n25378153]]></link>
		<description><![CDATA[Company to Host Conference Call on Monday, May 5 at 8:30 am EST]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 02 May 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/advisory+committee.html"><![CDATA[advisory committee]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Advanced Cell Technology's Executive Invited to Present Today to FDA Advisory Committee on Cellular Tissue Therapies]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_April_10/ai_n25147434]]></link>
		<description><![CDATA[ALAMEDA, Calif. -- Advanced Cell Technology, Inc. (OTCBB: ACTC) announced today that Jonathan H. Dinsmore Ph.D., Senior Vice President - Regulatory and Clinical, has been invited to present to the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research Advisory Committee on Cellular, Tissue and Gene Therapies. Dr....]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 10 Apr 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/advisory+committee.html"><![CDATA[advisory committee]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[therapy]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Lev Announces FDA's Blood Products Advisory Committee to Review Cinryze &#153;]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_March_13/ai_n24920732]]></link>
		<description><![CDATA[NEW YORK -- Lev Pharmaceuticals, Inc. (OTCBB: LEVP.OB) today announced that it has been advised that the Blood Products Advisory Committee BPAC for U.S. Food and Drug Administration FDA intends to review the Biologics License Application BLA for Cinryze (C1 inhibitor) on May 2, 2008, for the prophylactic treatment of...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 13 Mar 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/advisory+committee.html"><![CDATA[advisory committee]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[FDAAdvisoryCommittee.com Will Webcast the March 13th FDA Oncologic Drugs Advisory Committee (ODAC) Meeting, Powered by TalkPoint Technology]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200803/ai_n24390934]]></link>
		<description><![CDATA[TalkPoint, leading provider of the Tools, Technology and Services for Interactive  Internet Broadcasting  and FDAAdvisoryCommittee.com, the premiere live  webcast  and archive DVD library for FDA Advisory Committee Meetings, announced that TalkPoint will be powering the March 13th FDAAdvisoryCommittee.com webcast of the Oncologic Drugs Advisory Committee Meeting. ]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 11 Mar 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/advisory+committee.html"><![CDATA[advisory committee]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/webcast.html"><![CDATA[Webcast]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Theravance Receives Additional Information Regarding FDA Cancellation of Advisory Committee Meeting]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200803/ai_n24367404]]></link>
		<description><![CDATA[Theravance, Inc. (NASDAQ: THRX) announced today that it has been informed by the U.S. Food and Drug Administration FDA that the February 27th planned review of telavancin by the Anti-Infective Drugs Advisory Committee AIDAC was cancelled on February 23rd in order to allow time for the FDA to further evaluate...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 03 Mar 2008 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/advisory+committee.html"><![CDATA[advisory committee]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Rotarix® Receives Favorable Recommendation from FDA Advisory Committee]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Feb_21/ai_n24318612]]></link>
		<description><![CDATA[NEEDHAM, Mass. -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced that Rotarix([R]), an oral, two-dose rotavirus candidate vaccine to prevent rotavirus gastroenteritis in infants, received a favorable recommendation from the U.S. Food and Drug Administration's FDA Vaccines and Related Biological Products Advisory Committee VRBPAC. AVANT licensed the technology for Rotarix([R])...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 21 Feb 2008 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/advisory+committee.html"><![CDATA[advisory committee]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[FDA published today that it will not hold an advisory committee meeting on ceftobiprole in the treatment of complicated skin and skin structure infections]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200802/ai_n21413907]]></link>
		<description><![CDATA[Basilea Pharmaceutica (SWX: BSLN) announces that the US Food and Drug Administration FDA determined that the Anti-Infective Drugs Advisory Committee meeting scheduled for February 28, 2008 will not be held, as provided for under the provisions of the amendment of Section 505 of the Federal Food, Drug, and Cosmetic Act. ]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 13 Feb 2008 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/advisory+committee.html"><![CDATA[advisory committee]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[FDA Advisory Committee Process Changes]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5979/is_200801/ai_n24154744]]></link>
		<description><![CDATA[The Food and Drug Administration FDA announced on November 15 steps to strengthen its advisory committee processes in response to recent recommendations from the Institute of Medicine. The measures include proposed new guidance or procedures on advisoryThe Food and Drug Administration FDA announced on November 15 steps to strengthen its...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 01 Jan 2008 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/advisory+committee.html"><![CDATA[advisory committee]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Statement from the Consumer Healthcare Products Association on Todays FDA Advisory Committee Meeting on the Efficacy of Phenylephrine in the 10 Mg Oral Dose]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5554/is_200712/ai_n21800294]]></link>
		<description><![CDATA[To: NATIONAL EDITORSTo: NATIONAL EDITORS]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 14 Dec 2007 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/advisory+committee.html"><![CDATA[advisory committee]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Adolor and GlaxoSmithKline Announce FDA Advisory Committee to Review Entereg®  for the Management of Postoperative Ileus]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_Nov_28/ai_n27469296]]></link>
		<description><![CDATA[EXTON, Pa. & PHILADELPHIA -- Adolor Corporation (Nasdaq:ADLR) and GlaxoSmithKline (NYSE:GSK) announced today that the Gastrointestinal Drugs Advisory Committee to the U.S. Food and Drug Administration FDA will review Adolor's New Drug Application NDA for Entereg[R] alvimopan for the proposed indication of acceleration of time to upper and lower gastrointestinal...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 28 Nov 2007 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/advisory+committee.html"><![CDATA[advisory committee]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/glaxosmithkline+plc..html"><![CDATA[GlaxoSmithKline Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
		<category domain="tickers">GSK</category>
	</item>
	<item>
		<title><![CDATA[FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5570/is_200710/ai_n23660648]]></link>
		<description><![CDATA[PHILADELPHIA, October 17 /PRNewswire/ --    PHILADELPHIA, October 17 /PRNewswire/ --  ]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 16 Oct 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/advisory+committee.html"><![CDATA[advisory committee]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[FDA Advisory Committee Recommends Medtronic's Endeavor® Drug-Eluting Stent for Approval]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_Oct_10/ai_n27403867]]></link>
		<description><![CDATA[Next-Generation DES Represents Promising New Treatment Option for Coronary Artery Disease]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 10 Oct 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/advisory+committee.html"><![CDATA[advisory committee]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/medtronic+inc..html"><![CDATA[Medtronic Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MDT</category>
		<category domain="tickers">MDT</category>
	</item>
	<item>
		<title><![CDATA[Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin- Stimulating Agents in Treatment of Kidney Patients]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5554/is_200709/ai_n21913167]]></link>
		<description><![CDATA[To: MEDICAL EDITORSTo: MEDICAL EDITORS]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 12 Sep 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/advisory+committee.html"><![CDATA[advisory committee]]></category>
		<category domain="http://resources.bnet.com/topic/agent.html"><![CDATA[agent]]></category>
		<category domain="http://resources.bnet.com/topic/benefit.html"><![CDATA[benefit]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Amgen to Review Benefits, Risks of ESA Therapy in Chronic Renal Failure Patients at FDA Advisory Committee]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_Sept_11/ai_n27369312]]></link>
		<description><![CDATA[Company Recommends Hemoglobin Target of 10-12 g/dL as Risk Management Approach]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 11 Sep 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/advisory+committee.html"><![CDATA[advisory committee]]></category>
		<category domain="http://resources.bnet.com/topic/amgen+inc..html"><![CDATA[Amgen Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/benefit.html"><![CDATA[benefit]]></category>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMGN</category>
		<category domain="tickers">AMGN</category>
	</item>
	<item>
		<title><![CDATA[FDA Advisory Committee Unanimously Recommends Accelerated Approval of ISENTRESS&#153; , Merck's Investigational Oral Integrase Inhibitor, for Treatment of HIV]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_Sept_5/ai_n27364677]]></link>
		<description><![CDATA[WHITEHOUSE STATION, N.J. -- Merck & Co., Inc. announced today that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration FDA voted unanimously to recommend accelerated FDA approval of ISENTRESS[TM] raltegravir in combination with other antiretroviral therapy ART for the treatment of HIV infection in treatment-experienced patients...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 05 Sep 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/advisory+committee.html"><![CDATA[advisory committee]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Joint FDA Advisory Committee Recommends Approval of TYSABRI® for the Treatment of Moderate to Severe Crohn's Disease]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_August_1/ai_n27328808]]></link>
		<description><![CDATA[GAITHERSBURG, Md. -- Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced today that the Gastrointestinal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration FDA voted 12 in favor to 3 opposed, with 2 abstaining, to recommend...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 01 Aug 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/advisory+committee.html"><![CDATA[advisory committee]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Takeda Responds to the FDA Advisory Committee Recommendation.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5570/is_200707/ai_n23644113]]></link>
		<description><![CDATA[LONDON, July 31 /PRNewswire/ --    LONDON, July 31 /PRNewswire/ --  ]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 31 Jul 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/advisory+committee.html"><![CDATA[advisory committee]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/takeda.html"><![CDATA[Takeda]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Takeda Responds to the FDA Advisory Committee Recommendation]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_July_30/ai_n27326322]]></link>
		<description><![CDATA[DEERFIELD, Ill. -- Following a joint meeting today of the U.S. Food and Drug Administration FDA Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Takeda Global Research & Development TGRD underscores its position that ACTOS([R]) pioglitazone HCl offers a proven safety profile regarding...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 30 Jul 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/advisory+committee.html"><![CDATA[advisory committee]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/takeda.html"><![CDATA[Takeda]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
</channel>
</rss>
